CO-1686 (Rociletinib, AVL-301)
Catalog No. A13028
CO-1686是一种新型的口服靶向共价(不可逆)抑制剂,可抑制表皮生长因子受体(EGFR)的致癌突变形式,目前正在研究用于治疗非小细胞肺癌(NSCLC)。
Catalog Num | A13028 |
---|---|
M. Wt | 555.55 |
Formula | C27H28F3N7O3 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 1374640-70-6 |
Synonyms | CO1686; AVL-301; CNX-419 ;AVL 301; AVL301; CNX419 |
SMILES | CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC |
CO-1686是一种新型的口服靶向共价(不可逆)抑制剂,可抑制表皮生长因子受体(EGFR)的致癌突变形式,目前正在研究用于治疗非小细胞肺癌(NSCLC)。
In vitro (25°C) | DMSO | 91 mg/mL (163.8 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 1% DMSO+30% polyethylene glycol+1% Tween 80 | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18 mL | 90 mL | 180 mL |
0.5 mM | 3.6 mL | 18 mL | 36 mL |
1 mM | 1.8 mL | 9 mL | 18 mL |
5 mM | 0.36 mL | 1.8 mL | 3.6 mL |
*The above data is based on the productmolecular weight 555.55. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.